May 8 (Reuters) - Aeterna Zentaris Inc AEZS.TO :
* Aeterna Zentaris reports first quarter 2017 financial and operating results
* Aeterna Zentaris Inc - qtrly revenue $261,000 versus $242,000; qtrly loss per share $0.31
* Aeterna Zentaris Inc - do not anticipate conducting clinical trials of zoptrex with respect to any other indications
* Aeterna Zentaris Inc - co's focus has now shifted entirely to filing new drug application for macrilen Source text for Eikon: ID:nBw1LBQLva Further company coverage: AEZS.TO